Cargando…

SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice

DESIGN: Pharmacokinetic and pharmacodynamic parameters of cremophor-paclitaxel, nab-paclitaxel (human-albumin-bound paclitaxel, Abraxane) and a novel mouse-albumin-bound paclitaxel (m-nab-paclitaxel) were evaluated in genetically engineered mouse models (GEMMs) by liquid chromatography-tandem mass s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Neesse, Albrecht, Frese, Kristopher K, Chan, Derek S, Bapiro, Tashinga E, Howat, William J, Richards, Frances M, Ellenrieder, Volker, Jodrell, Duncan I, Tuveson, David A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2014
Materias:	Pancreatic Cancer
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4033275/ https://www.ncbi.nlm.nih.gov/pubmed/24067278 http://dx.doi.org/10.1136/gutjnl-2013-305559

Ejemplares similares

Anti-Tumour Efficacy of Capecitabine in a Genetically Engineered Mouse Model of Pancreatic Cancer
por: Courtin, Aurélie, et al.
Publicado: (2013)

Understanding the Complexity of Porous Graphitic Carbon (PGC) Chromatography: Modulation of Mobile-Stationary Phase Interactions Overcomes Loss of Retention and Reduces Variability
por: Bapiro, Tashinga E., et al.
Publicado: (2016)

Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma
por: Cook, Natalie, et al.
Publicado: (2012)

SPARC dependent collagen deposition and gemcitabine delivery in a genetically engineered mouse model of pancreas cancer
por: Ramu, Iswarya, et al.
Publicado: (2019)

A novel method for quantification of gemcitabine and its metabolites 2′,2′-difluorodeoxyuridine and gemcitabine triphosphate in tumour tissue by LC–MS/MS: comparison with (19)F NMR spectroscopy
por: Bapiro, Tashinga E., et al.
Publicado: (2011)

Effect of exercise therapy on sarcopenia in pancreatic cancer: a study protocol for a randomised controlled trial
por: Yoh, Kazunori, et al.
Publicado: (2018)

A randomised controlled trial of gemcitabine hydrochloride plus S-1 combination therapy versus gemcitabine hydrochloride therapy alone in pancreatic cancer patients aged ≥75 years: a study protocol for an open-label randomised feasibility study
por: Ishii, Hiroshi, et al.
Publicado: (2018)

Implication of exercise interventions on sleep disturbance in patients with pancreatic cancer: a study protocol for a randomised controlled trial
por: Yoh, Kazunori, et al.
Publicado: (2018)

Feasibility and efficacy of a multicomponent exercise medicine programme in patients with pancreatic cancer undergoing neoadjuvant therapy (the EXPAN trial): study protocol of a dual-centre, two-armed phase I randomised controlled trial
por: Luo, Hao, et al.
Publicado: (2021)

Clinical impact of physical exercise on sleep disorder as assessed by actigram in patients with chronic pancreatitis: a study protocol for a randomised controlled trial
por: Yoh, Kazunori, et al.
Publicado: (2018)

Moderately severe and severe acute pancreatitis : a systematic review of the outcomes in the USA and European Union-5
por: Sarri, Grammati, et al.
Publicado: (2019)

Novel multidisciplinary hub-and-spoke tertiary service for the management of severe acute pancreatitis
por: Nayar, Manu K, et al.
Publicado: (2021)

Social deprivation does not impact on acute pancreatitis severity and mortality: a single-centre study
por: Lim, Wei Boon, et al.
Publicado: (2023)

Incidence of acute pancreatitis among patients with leptospirosis requiring extracorporeal membrane oxygenation (ECMO): a descriptive study
por: Madrigal, Tristan Paulo R, et al.
Publicado: (2023)

Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer
por: Jacobetz, Michael A, et al.
Publicado: (2013)

Gemcitabine diphosphate choline is a major metabolite linked to the Kennedy pathway in pancreatic cancer models in vivo
por: Bapiro, T E, et al.
Publicado: (2014)

Conformity analysis to demonstrate reproducibility of target volumes for Margin-Intense Stereotactic Radiotherapy for borderline-resectable pancreatic cancer
por: Holyoake, Daniel L.P., et al.
Publicado: (2016)

Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma
por: Corrie, P. G., et al.
Publicado: (2020)

Does Concurrent Cholestasis Alter the Prognostic Value of Preoperatively Elevated CA19-9 Serum Levels in Patients with Pancreatic Head Adenocarcinoma?
por: Anger, Friedrich, et al.
Publicado: (2022)

A Modified Regimen of 21-day Nab-Paclitaxel Plus Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer: A Retrospective Real-World Study
por: Chang, Chen, et al.
Publicado: (2022)

Phase Ib and Expansion Study of Gemcitabine, Nab-Paclitaxel, and Ficlatuzumab in Patients With Metastatic Pancreatic Cancer
por: Perez, Kimberly, et al.
Publicado: (2023)

Depletion of Macrophages Improves Therapeutic Response to Gemcitabine in Murine Pancreas Cancer
por: Buchholz, Soeren M., et al.
Publicado: (2020)

Modified gemcitabine plus nab‐paclitaxel regimen in advanced pancreatic ductal adenocarcinoma
por: Rogers, Jane E., et al.
Publicado: (2020)

Impact of Borderline Resectability in Pancreatic Head Cancer on Patient Survival: Biology Matters According to the New International Consensus Criteria
por: Anger, Friedrich, et al.
Publicado: (2020)

Impact of SPARC expression on outcome in patients with advanced pancreatic cancer not receiving nab-paclitaxel: a pooled analysis from prospective clinical and translational trials
por: Ormanns, Steffen, et al.
Publicado: (2016)

Durable response for ampullary and duodenal adenocarcinoma with a nab‐paclitaxel plus gemcitabine ± cisplatin combination
por: Cen, Putao, et al.
Publicado: (2019)

Comparing the Efficacy and Safety of Gemcitabine plus Nab-Paclitaxel versus Gemcitabine Alone in Older Adults with Unresectable Pancreatic Cancer
por: Kobayashi, Satoshi, et al.
Publicado: (2022)

Discussion: Pancreatic Pathology
por: Jensen, Robert T.
Publicado: (1992)

Adjuvant Chemoradiation for Pancreatic Adenocarcinoma: The Johns Hopkins Hospital—Mayo Clinic Collaborative Study
por: Hsu, Charles C., et al.
Publicado: (2010)

Challenges in the Study of Adjuvant Chemoradiation After Pancreaticoduodenectomy
por: Crane, Christopher H., et al.
Publicado: (2009)

A Case of Gastric Heterotopic Pancreatitis Resected by Laparoscopic Surgery
por: Matsumoto, Takatsugu, et al.
Publicado: (2015)

The incidence of acute pancreatitis: impact of social deprivation, alcohol consumption, seasonal and demographic factors1
por: Roberts, SE, et al.
Publicado: (2013)

Outcomes of Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma in the Netherlands: A Nationwide Retrospective Analysis
por: de Rooij, Thijs, et al.
Publicado: (2015)

Skeletal Muscle Quality is Associated with Worse Survival After Pancreatoduodenectomy for Periampullary, Nonpancreatic Cancer
por: Van Rijssen, L. B., et al.
Publicado: (2016)

Risk of subsequent biliary malignancy in patients undergoing cyst excision for congenital choledochal cysts
por: Ohashi, Taku, et al.
Publicado: (2013)

Outcomes After Distal Pancreatectomy with Celiac Axis Resection for Pancreatic Cancer: A Pan-European Retrospective Cohort Study
por: Klompmaker, Sjors, et al.
Publicado: (2018)

Recurrence of Pancreatic Neuroendocrine Tumors and Survival Predicted by Ki67
por: Genç, C. G., et al.
Publicado: (2018)

Pathological Margin Clearance and Survival After Pancreaticoduodenectomy in a US and European Pancreatic Center
por: van Roessel, Stijn, et al.
Publicado: (2018)

Image-Guided Surgery in Patients with Pancreatic Cancer: First Results of a Clinical Trial Using SGM-101, a Novel Carcinoembryonic Antigen-Targeting, Near-Infrared Fluorescent Agent
por: Hoogstins, Charlotte E. S., et al.
Publicado: (2018)

Prognostic Nomogram for Disease-Specific Survival in Patients with Non-metastatic Ampullary Carcinoma After Surgery
por: Li, Huang-bao, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_bsp9tluc798c1josd0u17kd1ao